Dr. Reddy’s Expands Strategic Collaboration with Amgen in India

HYDERABAD, India–(BUSINESS WIRE)– Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
today announced that it has expanded its strategic collaboration with
Amgen, one of the world’s leading independent biotechnology companies,
to market and distribute three of Amgen’s medicines in India in the
therapy areas of oncology and osteoporosis. Under the terms of the
collaboration, Dr. Reddy’s will commercialise XGEVA^® (denosumab),
Vectibix^® (panitumumab) and Prolia^®
(denosumab) in India.

In 2015, Dr. Reddy’s announced an initial strategic collaboration with
Amgen to execute a full range of regulatory and commercial services to
seek approval of and launch Amgen’s Kyprolis® (carfilzomib), BLINCYTO®
(blinatumomab) and Repatha™ (evolocumab) in India. The collaboration
leverages the capabilities of both companies, combining Amgen’s
innovative therapies with Dr. Reddy’s deep understanding of patient and
physician needs in India.

M.V. Ramana, Executive Vice President and Head of Emerging markets and
India Business, Dr. Reddy’s Laboratories Limited, said, “We are
delighted to continue our relationship with Amgen as it strengthens our
constant endeavor to enhance patients’ access to novel treatment options
across therapy areas. These medicines provide unique treatment options
to physicians to address unmet medical need in the area of oncology and
osteoporosis.”

Penny Wan, Amgen Vice President and General Manager, Japan Asia Pacific
Region, said, ”We are happy to strengthen our relationship with Dr.
Reddy’s. Amgen is committed to addressing unmet medical needs of
patients in India, and we are pleased with the commitment Dr. Reddy’s
has demonstrated toward making our medicines available in India as
quickly as possible.”

XGEVA is a RANK ligand (RANKL) inhibitor and is approved in India for
the prevention of skeletal related events in patients with advanced
malignancies involving bone.

Vectibix is an epidermal growth factor receptor (EGFR) antagonist
approved in India for the treatment of adult patients with wild-type
KRAS metastatic colorectal cancer (m-CRC) as first line treatment as
monotherapy following disease progression, in wild type RAS m-CRC as
first-line combination with FOLFOX and in second line in combination
with FOLFIRI after prior treatment with fluoropyrimidine-based
chemotherapy (excluding irinotecan).

Prolia is a RANK ligand (RANKL) inhibitor approved in India for
treatment of post-menopausal women with osteoporosis at high risk for
fracture and also for treatment of increased bone mass in men with
osteoporosis. Often referred to as the « silent epidemic, » osteoporosis
is a global problem that is increasing in significance as the population
of the world both increases and ages. The World Health Organization
(WHO) has recently identified osteoporosis as a priority health issue
along with other major non-communicable diseases.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy’s operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words « may, » « will, » « should, » « expects, »
« plans, » « intends, » « anticipates, » « believes, » « estimates, » « predicts, »
« potential, » or « continue » and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency/severity of insured loss events,
(ii) mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v)
the impact of acquisitions or reorganization, including related
integration issues.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160916005336/en/